Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award
Crescendo Biologics Limited announces it is expanding its antibody drug conjugate (ADC) programme with the support of a Biomedical Catalyst Award from the UK’s innovation agency, Innovate UK. This feasibility award will enable the validation and development of Humabody Drug Conjugates (HDCs) a novel product format based on Crescendo’s Humabody™ antibody fragment technology which has huge potential for the treatment of a broad range of solid tumours.
Crescendo’s HDCs combine the targeting specificity of Humabody™ VH fragments with highly-potent toxin payloads. Humabody VH are the smallest antibody fragments (12kD) and as such have the potential for rapid, affinity-driven penetration of solid tumours and fast clearance from systemic circulation. This results in a high tumour-to-blood ratio and reduced systemic toxicity, thereby enhancing therapeutic index.
Crescendo’s expanded oncology programme builds on the Company’s increasing involvement in ADC development as the potential of Humabody technology to develop valuable HDC therapeutics is recognised. The new programme will involve Crescendo collaborating with an established player in the ADC space on the conjugation of a highly potent toxin to a Humabody fragment targeting prostate cancer and is part of the Company’s active partnering strategy in the ADC area.
Other news from the department research and development
